<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217190</url>
  </required_header>
  <id_info>
    <org_study_id>OND/CR/020/08-09</org_study_id>
    <nct_id>NCT01217190</nct_id>
    <nct_alias>NCT01216969</nct_alias>
  </id_info>
  <brief_title>Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets</brief_title>
  <acronym>01905/08-09</acronym>
  <official_title>Open-Label Randomized, Single Oral Dose, Two-Way Crossover Bioequivalence Study Comparing Ondansetron Orally Dissolving Film Strip 8 mg With Zofran Orally Disintegrating Tablets (ODT) (Containing Ondansetron 8 mg) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MonoSol Rx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquestive Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover&#xD;
      bioequivalence study with a 7-day washout between periods. Each treatment was administered&#xD;
      after an overnight (10 hours) fast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open label, balanced, randomized, two-treatment, two-period, randomized sequence&#xD;
      crossover study conducted in healthy adult male and female volunteers. Subjects checked into&#xD;
      the study center on Day -1 of each study period at least 12 hours prior to dosing on Day 1.&#xD;
      Subjects were served dinner between 8:00 pm to 8:30 pm to ensure minimum 10 hours fast prior&#xD;
      to dosing in both periods. Subjects received the 2 treatments in a randomized order with a&#xD;
      7-day washout between the 2 periods.&#xD;
&#xD;
      Treatment A: single dose of ondansetron ODFS 8 mg was orally administered, allowed to&#xD;
      dissolve, swallowed with saliva, followed with 240 mL room temperature drinking water&#xD;
&#xD;
      Treatment B: single dose of Zofran ODT (containing ondansetron 8 mg) was orally administered,&#xD;
      allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature drinking&#xD;
      water&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2008</start_date>
  <completion_date type="Actual">October 6, 2008</completion_date>
  <primary_completion_date type="Actual">September 26, 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two period study, two treatment, randomized sequence</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours</time_frame>
    <description>Maximum Plasma Concentration occurring at Tmax (Time to reach maximum concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours</time_frame>
    <description>Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours</time_frame>
    <description>Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Nausea and Vomiting, Postoperative</condition>
  <condition>Nausea With Vomiting Chemotherapy-Induced</condition>
  <arm_group>
    <arm_group_label>Ondansetron ODFS then Zofran ODT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Ondansetron Orally Dissolving Film Strip 8 mg followed by single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg with 7 days washout between the 2 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zofran ODT then Ondansetron ODFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg followed by single dose of Ondansetron Orally Dissolving Film Strip 8 mg with 7 days washout between the 2 periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron (ODFS)</intervention_name>
    <description>Test Article</description>
    <arm_group_label>Ondansetron ODFS then Zofran ODT</arm_group_label>
    <arm_group_label>Zofran ODT then Ondansetron ODFS</arm_group_label>
    <other_name>Ondansetron Orally Dissolving Film Strip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran (ODT)</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Ondansetron ODFS then Zofran ODT</arm_group_label>
    <arm_group_label>Zofran ODT then Ondansetron ODFS</arm_group_label>
    <other_name>Zofran Orally Disintegrating Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteer should have written informed consent.&#xD;
&#xD;
          -  Volunteer healthy adult within 18-45 years of age (inclusive).&#xD;
&#xD;
          -  Body mass index of 18.5 kg/m^2 and 25 kg/m^2, body weight not less than 50 kg.&#xD;
&#xD;
          -  Volunteer must be of normal health.&#xD;
&#xD;
          -  Volunteer should have a normal ECG, chest X-ray and vital signs.&#xD;
&#xD;
          -  If study volunteer is a female and is of child bearing potential practicing an&#xD;
             acceptable method of birth control for the duration of the study.&#xD;
&#xD;
        Criteria: Exclusion Criteria:&#xD;
&#xD;
          -  Volunteer doesn't understand the informed consent.&#xD;
&#xD;
          -  Volunteer with a history of hypersensitivity or idiosyncratic reaction to study drug&#xD;
             or any other related drug.&#xD;
&#xD;
          -  Volunteer having any evidence of impairment of renal, hepatic, cardiac, lung or&#xD;
             gastrointestinal function, by standard laboratory, imaging or monitoring procedures&#xD;
&#xD;
          -  Volunteer who smokes regularly, alcohol or drug abuse&#xD;
&#xD;
          -  Volunteer who has taken over the counter or prescribed medications&#xD;
&#xD;
          -  Volunteer with clinically significant abnormal values of laboratory parameters.&#xD;
&#xD;
          -  Volunteer who has participated in any other clinical investigation using experimental&#xD;
             drug or had bled more than 350 mL in the past 3 months.&#xD;
&#xD;
          -  Female volunteer demonstrating a positive pregnancy screen with urine pregnancy test&#xD;
             (strip method).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudershan Vishwanath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VIMTA VHS Research Centre</name>
      <address>
        <city>Adyar</city>
        <state>Chennai</state>
        <zip>600 113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2020</results_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence, safety, and tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The planned sample size was 48. Of the 48 participants enroll in the study, 46 completed the study.</recruitment_details>
      <pre_assignment_details>A total of 68 volunteers (52 males and 16 females) were screened for enrollment and a total of 48 volunteers (41 males and 7 females) were subsequently admitted to the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Ondansetron ODFS, Then Zofran ODT</title>
          <description>Participants first received a single oral dose of Ondansetron Orally Dissolving Film Strip (ODFS) 8 mg after an overnight fast of at least 10 hours. After a washout period of 7 days, they then received a single oral dose of Zofran Orally Disintegrating Tablet (ODT) containing ondansetron 8 mg after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="P2">
          <title>Experimental: Zofran ODT, Then Ondansetron ODFS</title>
          <description>Participants first received a single oral dose of Zofran Orally Disintegrating Tablet (ODT) containing ondansetron 8 mg after an overnight fast of at least 10 hours. After a washout period of 7 days, they then received a single oral dose of Ondansetron Oral Dissolving Film Strip (ODFS) 8 mg after an overnight fast of at least 10 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Dosing</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Dosing</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22">Two subjects withdrew for personal reasons (other than adverse event).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 48 subjects were entered into the study. Two did not complete.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Ondansetron ODFS, Then Zofran ODT</title>
          <description>24 participants completed treatment with Ondansetron ODSF 8 mg. After a washout period of 7 days, 24 of the 24 participants who completed the first treatment also completed treatment with Zofran ODT 8mg.</description>
        </group>
        <group group_id="B2">
          <title>Experimental: Zofran ODT, Then Ondansetron ODFS</title>
          <description>24 participants completed treatment with Zofran ODT 8 mg. After a washout period of 7 days, 22 of the 24 participants who completed the first treatment also completed treatment with Ondansetron ODSF 8 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All 24 who entered Ondansetron ODSF first, then Zofran ODT arm completed both periods.&#xD;
All 24 subjects who entered Zofran ODT first, then Ondansetron ODSF arm completed the first period, 22 of these 24 subjects completed the second period.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="6.08"/>
                    <measurement group_id="B2" value="28.7" spread="5.6"/>
                    <measurement group_id="B3" value="29.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>No subjects dropped out of Organestron ODFS, then Zofran ODT arm. Two subjects dropped out of Zofran ODT, then Oganestron ODFS arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum Plasma Concentration occurring at Tmax (Time to reach maximum concentration)</description>
        <time_frame>0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours</time_frame>
        <population>Pharmacokinetic analysis population comprised all subjects who received study drug in both study periods and completed the study. Two of the 24 subjects in the Zofran ODT then Ondansetron ODSF arm did not return for Period 2 for personal reasons other than adverse events (voluntary withdrawal).</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron ODFS</title>
            <description>Single dose of Ondansetron Orally Dissolving Film Strip (ODFS) 8 mg&#xD;
ODFS:Two-way cross-over study to compare ODFS 8 mg with Zofran Orally Disintegrating Table (ODT) containing ondansetron 8 mg</description>
          </group>
          <group group_id="O2">
            <title>Zofran ODT</title>
            <description>Single dose of Zofran (Ondansetron) Orally Disintegrating Tablet (ODT) containing ondansetron 8 mg&#xD;
Zofran (ODT): Two-way cross-over study to compare ODFS 8 mg with Zofran ODT 8 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum Plasma Concentration occurring at Tmax (Time to reach maximum concentration)</description>
          <population>Pharmacokinetic analysis population comprised all subjects who received study drug in both study periods and completed the study. Two of the 24 subjects in the Zofran ODT then Ondansetron ODSF arm did not return for Period 2 for personal reasons other than adverse events (voluntary withdrawal).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.282" spread="14.9177"/>
                    <measurement group_id="O2" value="41.108" spread="17.2442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCt</title>
        <description>Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration</description>
        <time_frame>0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours</time_frame>
        <population>46 subjects completed both Treatments. 2 subjects did not return for Period 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron ODFS</title>
            <description>Single dose of Ondansetron Orally Dissolving Film Strip 8 mg&#xD;
Ondansetron (ODS): Two-wy cross-over study to compare ondansetron ODSF with Zofran ODT</description>
          </group>
          <group group_id="O2">
            <title>Zofran ODT</title>
            <description>Single dose of Zofran ODT® Orally Disintegrating Tablet 8 mg&#xD;
Zofran (ODT): Two way cross-over study to compare ondansetron ODSF with Zofran ODT</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt</title>
          <description>Area Under Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration</description>
          <population>46 subjects completed both Treatments. 2 subjects did not return for Period 2.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.269" spread="83.2883"/>
                    <measurement group_id="O2" value="239.463" spread="100.0745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCinf</title>
        <description>Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity</description>
        <time_frame>0,0.33,0.67,1,1.33,1.67,2,2.33,2.67,3,4,6,8,10,12,15,18,24 hours</time_frame>
        <population>46 subjects completed both periods. 2 subjects did not complete period 2</population>
        <group_list>
          <group group_id="O1">
            <title>Ondansetron ODFS</title>
            <description>Single dose of Ondansetron Orally Dissolving Film Strip 8 mg&#xD;
Ondansetron (ODS): Two-wy cross-over study to compare ondansetron ODSF with Zofran ODT</description>
          </group>
          <group group_id="O2">
            <title>Zofran ODT</title>
            <description>Single dose of Zofran (Ondansetron) ODT® Orally Disintegrating Tablets 8 mg&#xD;
Zofran (ODT): Two way cross-over study to compare ondansetron ODSF with Zofran ODT</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf</title>
          <description>Area Under Plasma Concentration-Time Curve From Time Zero to Time Infinity</description>
          <population>46 subjects completed both periods. 2 subjects did not complete period 2</population>
          <units>nghr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.032" spread="88.2551"/>
                    <measurement group_id="O2" value="250.673" spread="107.9654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over the full course of the study (approximately 1 month for each treatment arm).</time_frame>
      <desc>Safety Population included all participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ondansetron ODFS</title>
          <description>Single dose of Ondansetron Orally Dissolving Film Strip (ODFS) 8 mg&#xD;
ODFS: Two-way cross-over study to compare ODFS 8 mg with Zofran Orally Disintegrating Tablet (ODT) containing ondansetron 8 mg</description>
        </group>
        <group group_id="E2">
          <title>Zofran ODT</title>
          <description>Single dose of Zofran Orally Disintegrating Tablet (ODT) containing ondansetron 8 mg&#xD;
Zofran ODT: Two-way cross-over study to compare ODFS 8 mg with Zofran ODT 8 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <description>Increased eosinophil count</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>Decreased platelet count</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <description>Increased lymphocyte count</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <description>WBC count increased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Increased AST</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total bilirubin increased</sub_title>
                <description>Increased total bilirubin</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Increased ALT</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Upper respiratory tract infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>Par Pharmaceutical</organization>
      <phone>1-800-828-9393</phone>
      <email>DrugInfo@strativapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

